Archives

by in
Entry Author Date Location
Cancer Immunotherapy Companies: Looking Forward and Looking Back 03/02/15 Seattle
Bellicum CEO Reflects on Rise From Baylor to Houston Biotech Darling 02/26/15 Texas
West Coast Biotech Roundup: Laguna, SeaGen, Unchained, DME & More 02/19/15 San Francisco
It Had to be You: Why Roche Was The Lone Suitor For Foundation 01/16/15 Boston
West Coast Biotech Roundup: Hep C, 23andMe, Kite, Cash, Isis & More 01/08/15 San Francisco
Don’t Get Comfortable: 5 Biopharma Flashpoints to Consider in 2015 01/06/15 National
Larry Corey, Cofounder of 2014 Top Biotech Juno: “It’s No Outlier” 01/05/15 Seattle
With $2B Market Cap and New Shareholder Rules, Juno Ready for Debut 12/18/14 Seattle
ASH Roundup: Immunotherapy Stars, Gene Therapy Leaps Ahead 12/11/14 San Francisco
Immunotherapy Confidence (And Audience) Abundant At ASH T-Cell Talk 12/08/14 National
More Biotechs Belly-Up These Days but Dendreon Still “One of a Kind” 12/02/14 National
With Souped-Up Rituxan, Unum Plots First Foray Into T-Cell Therapy 12/01/14 Boston
Juno, Less Than a Year Old, Lines up IPO to Fund Cancer Work 11/17/14 Seattle
What Early Looks From ASH Tell Us About Cancer Immunotherapy 11/07/14 National
Sanofi-Genzyme Joins $12M Round for T-Cell Therapy Startup, Unum 10/21/14 Boston
With $310M and Public Investors Aboard, Is a Juno IPO Next? 08/05/14 Seattle
Kite Pharma Garners $127,500,000 New Financing 06/19/14 San Diego
Kite Pharma Garners $50,000,000 New Round 04/28/14 San Diego
Kite Pharma Obtains $20,000,000 Series A Funding 05/15/13 San Diego
Kite Pharma Garners $250,000 New Round 12/14/12 San Diego
Kite Pharma Secures $250,000 New Funding 12/14/12 San Diego
Kite Pharma Obtains $15,000,000 Series A Funding Round 03/09/11 San Diego
Page 1 of 1